Full Press Release Details
Life Sciences to Host Investor Update Call
2 December 2020 at 4:15 p.m. ET
NEW YORK and LONDON - 1 December
2020 (GLOBE NEWSWIRE) - Tiziana Life Sciences plc (NASDAQ: TLSA) ("Tiziana" or the "Company"),
a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced
its CEO and CSO Dr. Kunwar Shailubhai will host a conference call on Wednesday, 2 December 2020 at 4:15 p.m. ET to provide updates
on the Company. Dr Shailubhai will provide updates on the Company's proposed move from AIM to the Standard Segment of the
Main Market of the London Stock Exchange, ongoing clinical trials, as well as other recent developments in Tiziana Life Sciences.
| Date: | Wednesday, 2 December 2020 |
| Time: | 4:15 p.m. Eastern Time |
| Live Call: | +1-877-425-9470 (U.S. Toll-Free) or +1-201-389-0878 (International) |
| Webcast: | http://public.viavid.com/index.php?id=142634 |
For interested individuals unable to join
the conference call, a dial-in replay of the call will be available until 16 December 2020 and can be accessed by dialing +1-844-512-2921
(U.S. Toll Free) or +1-412-317-6671 (International) and entering replay pin number: 13713850.
About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology
company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In
addition to Milciclib, the Company is also developing Foralumab for liver diseases. Foralumab is the only fully human anti-CD3
monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune
and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes
(T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is
accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced
inflammation, especially for treatment of COVID-19 patients.
For further enquiries:
United Kingdom Investors:
United States Investors: